Influenza vaccine

1. A method comprising administering a composition to a mammal, said composition comprising at least one ISCOM matrix and at least one ectodomain from at least one hemagglutinin domain and at least one isolated ectodomain from at least one neuraminidase domain from one or more influenza virus, wherein the ectodomains represent ectodomains being isolated from the influenza virus, the isolated ectodomains being isolated from the rest of the hemagglutinin and neuraminidase proteins; wherein the ectodomains are present in the composition at a ratio of neuraminidase ectodomain to hemagglutinin ectodomain that is greater than that of wild type influenza virus; and wherein the at least one ISCOM matrix comprises at least one saponin and at least one lipid.

2. The method of claim 1 , wherein one or more of the isolated ectodomains from at least one hemagglutinin domain and one or more of the isolated ectodomains from at least one neuraminidase domain are presented as hybrid proteins comprising at least one protein or portion thereof not of influenza virus.

3. The method according to claim 1 , wherein one or more of the isolated ectodomains from at least one hemagglutinin domain and one or more of the isolated ectodomains from at least one neuraminidase domain are a head domain.

4. The method according to claim 1 , wherein the influenza virus is chosen from sub serotypes of influenza e.g. from HxNy, wherein x is 1-16 and y is 1-9.

5. The method according to claim 4 , wherein the influenza virus is chosen from the group consisting of 1918 H1N1 influenza virus (A/South Carolina/1/18), 2004 H5N1 (A/Vietnam/1203/04), H1N1 influenza virus (A/California/07/2009), H1N1 influenza virus (A/California/04/2009), H1N1 influenza virus (A/California/09/2009), H1N1 influenza virus (A/Kentucky/UR06-0258/2007), and H5N1 influenza virus (A/turkey/Turkey/1/2005).

6. The method according to claim 1 , wherein the composition comprises 1-5 ectodomains from at least one hemagglutinin domain and 1-5 head domains from at least one neuraminidase domain.

7. The method according to claim 6 , wherein the at least one hemagglutinin ectodomain is chosen from the trimeric HA extodomain (a.a.17-522) of the A/California/09/2009.

8. The method according to claim 6 , wherein the at least one neuraminidase head domain is chosen from the tetrameric NA head domain (a.a.75-469) of the H1N1 influenza virus (A/California/09/2009).

9. The method according to claim 1 , further comprising at least one of an additive, an excipient, and a further adjuvant.

10. The method according to claim 1 , wherein the mammal is selected from the group consisting of a human, a cat, a dog, a horse, a bird, a cattle, bovine species, a swine, sheep, a goats, a ferret, and a mink.

11. The method of claim 1 , wherein the composition is chosen from a group consisting of an immune stimulating medicine, immune modulating pharmaceutical, and a vaccine against influenza.

12. The method of claim 1 , wherein the ISCOM matrix comprises separate ISCOM matrix particles containing Fraction A and Fraction C.

13. The method of claim 12 , wherein the separate ISCOM matrix particles are present in a composition of about 70% (w/w) Fraction A ISCOM matrix particles and about 30% (w/w) Fraction C ISCOM matrix particles.

14. The method of claim 12 , wherein the separate ISCOM matrix particles are present in a composition of about 85% (w/w) Fraction A ISCOM matrix particles and about 15% (w/w) Fraction C ISCOM matrix particles.

15. The method of claim 1 , wherein the ISCOM matrix comprises ISCOM matrix particles comprising a mixture of Fraction A ISCOM matrix and Fraction C ISCOM matrix.

16. The method of claim 15 , wherein the mixture comprises about 70% (w/w) Fraction A ISCOM matrix and about 30% (w/w) Fraction C ISCOM matrix.

17. The method of claim 15 , wherein the mixture comprises about 85% (w/w) Fraction A ISCOM matrix and about 15% (w/w) Fraction C ISCOM matrix.